Novo Nordisk: haemophilia drug safe and effective

(CercleFinance.com) - Novo Nordisk's concizumab demonstrated a favourable safety profile and clinical proof of concept for the prevention of bleeding episodes in patients with haemophilia, according to two phase-2 trials presented by the Danish drugmaker today.


The phase-2 trials showed annual bleeding rates comparable to factor prophylaxis despite many patients with haemophilia A and haemophilia A/B with inhibitors being undertreated due to conservative dosing rules, the firm said.

Novo also said that new five-year interim data showed that nonacog beta pegol (N9-GP) was effective and well tolerated for the prevention and treatment of bleeding in children with haemophilia B.

The shares of Novo Nordisk are currently down 1.5% in Copenhagen.

Copyright (c) 2019 CercleFinance.com. All rights reserved.